Annual Net Income
-$226.54 M
+$20.58 M+8.33%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual net profit is currently -$226.54 million, with the most recent change of +$20.58 million (+8.33%) on 31 December 2023. During the last 3 years, it has fallen by -$43.73 million (-23.92%). BCRX annual net income is now -4619.56% below its all-time high of -$4.80 million, reached on 31 December 1998.BCRX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$14.03 M
-$1.36 M-10.72%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly net profit is currently -$14.03 million, with the most recent change of -$1.36 million (-10.72%) on 30 September 2024. Over the past year, it has increased by +$22.12 million (+61.18%). BCRX quarterly net income is now -192.62% below its all-time high of $15.15 million, reached on 31 December 2009.BCRX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$123.82 M
+$22.12 M+15.15%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM net profit is currently -$123.82 million, with the most recent change of +$22.12 million (+15.15%) on 30 September 2024. Over the past year, it has increased by +$112.53 million (+47.61%). BCRX TTM net income is now -8154.47% below its all-time high of -$1.50 million, reached on 30 June 1999.BCRX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.3% | +61.2% | +47.6% |
| 3 y3 years | -23.9% | +76.1% | +45.4% |
| 5 y5 years | -123.7% | +62.7% | +7.4% |
BCRX Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -23.9% | +8.3% | -10.7% | +81.4% | at high | +49.9% |
| 5 y | 5 years | -123.7% | +8.3% | -435.2% | +81.4% | -13.7% | +49.9% |
| alltime | all time | -4619.6% | +8.3% | -192.6% | +81.4% | -8154.5% | +49.9% |
BioCryst Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.03 M(+10.7%) | -$123.82 M(-15.2%) |
| June 2024 | - | -$12.67 M(-64.2%) | -$145.93 M(-30.0%) |
| Mar 2024 | - | -$35.38 M(-42.7%) | -$208.59 M(-7.9%) |
| Dec 2023 | -$226.54 M(-8.3%) | -$61.73 M(+70.8%) | -$226.54 M(-4.2%) |
| Sept 2023 | - | -$36.15 M(-52.0%) | -$236.35 M(-2.6%) |
| June 2023 | - | -$75.33 M(+41.2%) | -$242.72 M(+7.3%) |
| Mar 2023 | - | -$53.33 M(-25.5%) | -$226.25 M(-8.4%) |
| Dec 2022 | -$247.12 M(+34.3%) | -$71.54 M(+68.3%) | -$247.12 M(+27.8%) |
| Sept 2022 | - | -$42.52 M(-27.8%) | -$193.35 M(-7.8%) |
| June 2022 | - | -$58.86 M(-20.7%) | -$209.63 M(+8.1%) |
| Mar 2022 | - | -$74.20 M(+317.3%) | -$193.97 M(+5.4%) |
| Dec 2021 | -$184.06 M(+0.7%) | -$17.78 M(-69.8%) | -$184.06 M(-18.8%) |
| Sept 2021 | - | -$58.80 M(+36.1%) | -$226.78 M(+5.9%) |
| June 2021 | - | -$43.20 M(-32.8%) | -$214.09 M(+2.2%) |
| Mar 2021 | - | -$64.28 M(+6.3%) | -$209.50 M(+14.6%) |
| Dec 2020 | -$182.81 M(+67.9%) | -$60.49 M(+31.2%) | -$182.81 M(+46.3%) |
| Sept 2020 | - | -$46.12 M(+19.4%) | -$124.94 M(+7.3%) |
| June 2020 | - | -$38.61 M(+2.7%) | -$116.42 M(+0.8%) |
| Mar 2020 | - | -$37.60 M(+1334.0%) | -$115.44 M(+6.0%) |
| Dec 2019 | -$108.90 M(+7.6%) | -$2.62 M(-93.0%) | -$108.90 M(-18.6%) |
| Sept 2019 | - | -$37.59 M(-0.1%) | -$133.71 M(+6.4%) |
| June 2019 | - | -$37.63 M(+21.2%) | -$125.71 M(+18.0%) |
| Mar 2019 | - | -$31.05 M(+13.2%) | -$106.53 M(+5.2%) |
| Dec 2018 | -$101.25 M(+53.9%) | -$27.43 M(-7.3%) | -$101.25 M(+8.4%) |
| Sept 2018 | - | -$29.60 M(+60.5%) | -$93.36 M(+18.3%) |
| June 2018 | - | -$18.45 M(-28.4%) | -$78.90 M(+2.0%) |
| Mar 2018 | - | -$25.78 M(+31.9%) | -$77.34 M(+17.6%) |
| Dec 2017 | -$65.78 M(+19.3%) | -$19.54 M(+29.1%) | -$65.78 M(+29.6%) |
| Sept 2017 | - | -$15.13 M(-10.4%) | -$50.74 M(+7.7%) |
| June 2017 | - | -$16.89 M(+18.8%) | -$47.14 M(+1.3%) |
| Mar 2017 | - | -$14.22 M(+215.8%) | -$46.53 M(-15.6%) |
| Dec 2016 | -$55.14 M(+28.2%) | -$4.50 M(-60.9%) | -$55.14 M(-19.8%) |
| Sept 2016 | - | -$11.53 M(-29.2%) | -$68.78 M(-4.3%) |
| June 2016 | - | -$16.28 M(-28.7%) | -$71.87 M(+41.8%) |
| Mar 2016 | - | -$22.83 M(+25.9%) | -$50.69 M(+17.8%) |
| Dec 2015 | -$43.02 M(-4.8%) | -$18.14 M(+24.0%) | -$43.02 M(+17.7%) |
| Sept 2015 | - | -$14.62 M(-398.3%) | -$36.56 M(+19.2%) |
| June 2015 | - | $4.90 M(-132.3%) | -$30.67 M(-38.9%) |
| Mar 2015 | - | -$15.16 M(+29.9%) | -$50.22 M(+11.1%) |
| Dec 2014 | -$45.19 M(+50.1%) | -$11.67 M(+33.7%) | -$45.19 M(+16.0%) |
| Sept 2014 | - | -$8.73 M(-40.4%) | -$38.95 M(+1.9%) |
| June 2014 | - | -$14.65 M(+44.5%) | -$38.22 M(+6.9%) |
| Mar 2014 | - | -$10.14 M(+86.7%) | -$35.74 M(+18.7%) |
| Dec 2013 | -$30.11 M(-23.0%) | -$5.43 M(-32.1%) | -$30.11 M(-15.7%) |
| Sept 2013 | - | -$8.00 M(-34.3%) | -$35.73 M(-4.5%) |
| June 2013 | - | -$12.17 M(+170.1%) | -$37.43 M(-0.3%) |
| Mar 2013 | - | -$4.51 M(-59.2%) | -$37.53 M(-4.0%) |
| Dec 2012 | -$39.08 M(-31.4%) | -$11.05 M(+13.9%) | -$39.08 M(-5.2%) |
| Sept 2012 | - | -$9.70 M(-21.0%) | -$41.22 M(-10.4%) |
| June 2012 | - | -$12.28 M(+102.8%) | -$45.98 M(-8.0%) |
| Mar 2012 | - | -$6.05 M(-54.1%) | -$49.97 M(-12.2%) |
| Dec 2011 | -$56.95 M(+68.2%) | -$13.19 M(-8.8%) | -$56.95 M(+5.5%) |
| Sept 2011 | - | -$14.46 M(-11.1%) | -$53.96 M(+7.1%) |
| June 2011 | - | -$16.27 M(+24.9%) | -$50.36 M(+13.7%) |
| Mar 2011 | - | -$13.03 M(+27.7%) | -$44.28 M(+30.8%) |
| Dec 2010 | -$33.85 M(+151.7%) | -$10.20 M(-6.1%) | -$33.85 M(+298.2%) |
| Sept 2010 | - | -$10.86 M(+6.6%) | -$8.50 M(+2.9%) |
| June 2010 | - | -$10.19 M(+292.8%) | -$8.26 M(+22.3%) |
| Mar 2010 | - | -$2.60 M(-117.1%) | -$6.75 M(-49.8%) |
| Dec 2009 | -$13.45 M | $15.15 M(-242.6%) | -$13.45 M(-27.4%) |
| Sept 2009 | - | -$10.63 M(+22.4%) | -$18.53 M(+9.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$8.68 M(-6.5%) | -$16.90 M(-19.2%) |
| Mar 2009 | - | -$9.29 M(-192.3%) | -$20.93 M(-15.4%) |
| Dec 2008 | -$24.73 M(-14.9%) | $10.07 M(-212.0%) | -$24.73 M(-33.3%) |
| Sept 2008 | - | -$8.99 M(-29.2%) | -$37.09 M(-5.1%) |
| June 2008 | - | -$12.71 M(-3.0%) | -$39.07 M(+17.2%) |
| Mar 2008 | - | -$13.10 M(+473.6%) | -$33.33 M(+14.7%) |
| Dec 2007 | -$29.06 M(-33.4%) | -$2.28 M(-79.2%) | -$29.06 M(-21.1%) |
| Sept 2007 | - | -$10.98 M(+57.7%) | -$36.82 M(-11.1%) |
| June 2007 | - | -$6.96 M(-21.1%) | -$41.44 M(-7.0%) |
| Mar 2007 | - | -$8.82 M(-12.2%) | -$44.56 M(+2.2%) |
| Dec 2006 | -$43.62 M(+67.1%) | -$10.05 M(-35.6%) | -$43.62 M(+7.1%) |
| Sept 2006 | - | -$15.60 M(+54.7%) | -$40.73 M(+24.3%) |
| June 2006 | - | -$10.08 M(+27.9%) | -$32.77 M(+15.7%) |
| Mar 2006 | - | -$7.88 M(+10.1%) | -$28.34 M(+8.6%) |
| Dec 2005 | -$26.10 M(+23.7%) | -$7.16 M(-6.3%) | -$26.10 M(+7.7%) |
| Sept 2005 | - | -$7.64 M(+35.4%) | -$24.23 M(+10.7%) |
| June 2005 | - | -$5.65 M(+0.1%) | -$21.88 M(+2.8%) |
| Mar 2005 | - | -$5.64 M(+6.7%) | -$21.29 M(+0.9%) |
| Dec 2004 | -$21.10 M(+66.2%) | -$5.29 M(-0.1%) | -$21.10 M(+10.7%) |
| Sept 2004 | - | -$5.30 M(+4.7%) | -$19.07 M(+11.0%) |
| June 2004 | - | -$5.06 M(-7.4%) | -$17.18 M(+11.7%) |
| Mar 2004 | - | -$5.46 M(+68.1%) | -$15.37 M(+21.1%) |
| Dec 2003 | -$12.70 M(-25.0%) | -$3.25 M(-4.7%) | -$12.70 M(+4.2%) |
| Sept 2003 | - | -$3.41 M(+4.8%) | -$12.18 M(-0.0%) |
| June 2003 | - | -$3.25 M(+16.6%) | -$12.19 M(-13.5%) |
| Mar 2003 | - | -$2.79 M(+1.9%) | -$14.10 M(-16.7%) |
| Dec 2002 | -$16.93 M(+239.5%) | -$2.74 M(-19.9%) | -$16.93 M(-11.7%) |
| Sept 2002 | - | -$3.42 M(-33.8%) | -$19.17 M(+25.0%) |
| June 2002 | - | -$5.16 M(-8.1%) | -$15.34 M(+66.4%) |
| Mar 2002 | - | -$5.62 M(+12.8%) | -$9.22 M(+84.9%) |
| Dec 2001 | -$4.99 M(-56.9%) | -$4.98 M(-1293.8%) | -$4.99 M(+169.5%) |
| Sept 2001 | - | $417.00 K(-56.5%) | -$1.85 M(-43.0%) |
| June 2001 | - | $958.00 K(-169.3%) | -$3.25 M(-41.4%) |
| Mar 2001 | - | -$1.38 M(-24.9%) | -$5.54 M(-52.2%) |
| Dec 2000 | -$11.58 M(+118.4%) | -$1.84 M(+87.9%) | -$11.58 M(+14.2%) |
| Sept 2000 | - | -$980.00 K(-26.4%) | -$10.14 M(-10.7%) |
| June 2000 | - | -$1.33 M(-82.1%) | -$11.36 M(+10.0%) |
| Mar 2000 | - | -$7.42 M(+1756.0%) | -$10.32 M(+94.8%) |
| Dec 1999 | -$5.30 M(+10.4%) | -$400.00 K(-81.8%) | -$5.30 M(-17.2%) |
| Sept 1999 | - | -$2.20 M(+633.3%) | -$6.40 M(+326.7%) |
| June 1999 | - | -$300.00 K(-87.5%) | -$1.50 M(-64.3%) |
| Mar 1999 | - | -$2.40 M(+60.0%) | -$4.20 M(-12.5%) |
| Dec 1998 | -$4.80 M(-54.7%) | -$1.50 M(-155.6%) | -$4.80 M(-22.6%) |
| Sept 1998 | - | $2.70 M(-190.0%) | -$6.20 M(-45.6%) |
| June 1998 | - | -$3.00 M(0.0%) | -$11.40 M(+8.6%) |
| Mar 1998 | - | -$3.00 M(+3.4%) | -$10.50 M(-0.9%) |
| Dec 1997 | -$10.60 M(+37.7%) | -$2.90 M(+16.0%) | -$10.60 M(+8.2%) |
| Sept 1997 | - | -$2.50 M(+19.0%) | -$9.80 M(0.0%) |
| June 1997 | - | -$2.10 M(-32.3%) | -$9.80 M(+10.1%) |
| Mar 1997 | - | -$3.10 M(+47.6%) | -$8.90 M(+15.6%) |
| Dec 1996 | -$7.70 M(-10.5%) | -$2.10 M(-16.0%) | -$7.70 M(-1.3%) |
| Sept 1996 | - | -$2.50 M(+108.3%) | -$7.80 M(+8.3%) |
| June 1996 | - | -$1.20 M(-36.8%) | -$7.20 M(-5.3%) |
| Mar 1996 | - | -$1.90 M(-13.6%) | -$7.60 M(-11.6%) |
| Dec 1995 | -$8.60 M(+24.6%) | -$2.20 M(+15.8%) | -$8.60 M(+4.9%) |
| Sept 1995 | - | -$1.90 M(+18.8%) | -$8.20 M(+3.8%) |
| June 1995 | - | -$1.60 M(-44.8%) | -$7.90 M(-3.7%) |
| Mar 1995 | - | -$2.90 M(+61.1%) | -$8.20 M(+18.8%) |
| Dec 1994 | -$6.90 M | -$1.80 M(+12.5%) | -$6.90 M(+35.3%) |
| Sept 1994 | - | -$1.60 M(-15.8%) | -$5.10 M(+45.7%) |
| June 1994 | - | -$1.90 M(+18.8%) | -$3.50 M(+118.8%) |
| Mar 1994 | - | -$1.60 M | -$1.60 M |
FAQ
- What is BioCryst Pharmaceuticals annual net profit?
- What is the all time high annual net income for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual net income year-on-year change?
- What is BioCryst Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly net income year-on-year change?
- What is BioCryst Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM net income year-on-year change?
What is BioCryst Pharmaceuticals annual net profit?
The current annual net income of BCRX is -$226.54 M
What is the all time high annual net income for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual net profit is -$4.80 M
What is BioCryst Pharmaceuticals annual net income year-on-year change?
Over the past year, BCRX annual net profit has changed by +$20.58 M (+8.33%)
What is BioCryst Pharmaceuticals quarterly net profit?
The current quarterly net income of BCRX is -$14.03 M
What is the all time high quarterly net income for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly net profit is $15.15 M
What is BioCryst Pharmaceuticals quarterly net income year-on-year change?
Over the past year, BCRX quarterly net profit has changed by +$22.12 M (+61.18%)
What is BioCryst Pharmaceuticals TTM net profit?
The current TTM net income of BCRX is -$123.82 M
What is the all time high TTM net income for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM net profit is -$1.50 M
What is BioCryst Pharmaceuticals TTM net income year-on-year change?
Over the past year, BCRX TTM net profit has changed by +$112.53 M (+47.61%)